SCHEMBL5036203

SCHEMBL5036203

COC(=O)Nc1nc2c(OC)ccc(-c3ccc(F)cc3)c2o1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
PKM P14618 1/20 0.41
ABL1 P00519 2/20 0.39
AURKA O14965 1/20 0.39
DYRK3 O43781 1/20 0.39
ROCK2 O75116 1/20 0.39
RPS6KA5 O75582 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
CHEK2 O96017 1/20 0.39
NTRK1 P04629 1/20 0.39
INSR P06213 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
LYN P07948 1/20 0.39
RET P07949 1/20 0.39
MET P08581 1/20 0.39
ROS1 P08922 1/20 0.39
FGFR1 P11362 1/20 0.39
SRC P12931 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5037699 0.89 ADCY1 (0.51) MAPTKDM4ELMNAADCY1OPRK1
SCHEMBL5131523 0.88 HTT (0.43) ALDH1A1ABL1AURKADYRK3ROCK2
SCHEMBL5037775 0.87 ALDH1A1 (0.45) ALDH1A1ABL1MAPTPOLBKMT2A
SCHEMBL5036500 0.84 HTT (0.54) ALDH1A1MAPTKDM4ELMNAADCY1
SCHEMBL5036142 0.83 KMT2A (0.46) ALDH1A1PKMMAPTKDM4ELMNA
SCHEMBL5033495 0.82 ADCY1 (0.42) ALDH1A1MAPTKDM4ELMNAADCY1
SCHEMBL5037899 0.81 ADCY1 (0.44) ABL1MAPTKDM4ELMNAADCY1
SCHEMBL5033611 0.81 ADORA2A (0.47) ALDH1A1MAPTKDM4ELMNAADCY1
SCHEMBL5040819 0.80 ADORA2A (0.47) ALDH1A1MAPTKDM4ELMNAADCY1
SCHEMBL5033620 0.78 ADORA2A (0.45) ALDH1A1MAPTKDM4ELMNAADCY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1587799-B1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-03-12 EP disclosed
US-6992083-B2 deiodination/arylation, acylation or hydrogenation of a substituted 4-methoxy-bezoxazole derivative; adenosine receptor ligands; Parkinson's and Alzheimer's Diseases; 2-Chloromethyl-N-[7-(4-fluoro-phenyl)-4-methoxy-benzooxazol-2-yl]-isonicotinamide HOFFMAN-LA ROCHE INC. (US) 2006-01-31 US disclosed
EP-1587799-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-26 EP disclosed
US-20040152702-A1 Benzoxazol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-08-05 US disclosed
WO-2004063177-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152702-A1 Benzoxazol derivatives P2RX3, P2RX2, P2RX1 ALDH1A1 1200/4885PKM 1634/4885ABL1 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.